IP Library › Granted Patent US 12,702,688
Granted Patent B2
US 12,702,688 · App. 17/012,771 · Granted Aug 11, 2026

Stable frozen virus formulation

Inventors: Jennifer R. Litowski (Arlington, MA); Christine Claudia Siska (Seattle, WA); Bruce Arthur Kerwin (Bainbridge Island, WA)
Assignee: AMGEN INC.
A61K35/763C12N7/00C12N2710/16621C12N2710/16632
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,702,688
App. No.
17/012,771
Granted
Aug 11, 2026
Kind
B2
Abstract

A live virus composition that maintains infectivity and provides improved virus stability during one or more freeze/thaw cycles and/or during long term storage in a liquid state at temperatures ranging from just above freezing to ambient temperatures.

Claims (45)

1 . A live virus liquid composition comprising:

a herpes simplex-1 virus;

partially hydrolyzed gelatin at a concentration of about 0.5% (w/v);

sorbitol at a concentration of about 2% (w/v);

sodium chloride at a concentration of about 50 mM to about 250 mM; and

sodium phosphate at a concentration of about 80 mM to about 120 mM;

wherein the composition is at pH 7-8.

2 . The live virus liquid composition according to claim 1 , wherein the composition further comprises sucrose at a concentration of about 9% (w/v) to about 15% (w/v).

3 . The live virus liquid composition according to claim 1 , wherein the composition further comprises myo-inositol at a concentration of about 4% (w/v).

4 . The live virus liquid composition according to claim 1 , wherein the composition comprises sodium phosphate at a concentration of about 102 mM.

5 . The live virus liquid composition according to claim 1 or 3 , wherein the herpes simplex-1 virus is selected from the group consisting of talimogene la herparepvec, G207, OrienX010, NV1020, and M032.

6 . The live virus liquid composition according to claim 5 , wherein the herpes simplex-1 virus is talimogene laherparepvec.

7 . The live virus liquid composition according to claim 1 , wherein the composition is a frozen composition.

8 . The live virus liquid composition according to claim 1 or 3 , wherein the composition is at about pH 7.4.

9 . The live virus liquid composition according to claim 1 , wherein said composition comprises sodium chloride at a concentration of about 145 mM.

10 . A method for killing tumor cells in a patient comprising administering to a subject in need thereof a live virus liquid composition under conditions effective to kill tumor cells in the patient, wherein said live virus composition comprises:

a herpes simplex virus;

partially hydrolyzed gelatin at a concentration of about 0.5% (w/v);

sorbitol at a concentration of about 2% (w/v);

sodium chloride; and

sodium phosphate,

wherein the composition is at pH 7-8.

11 . The method for killing tumor cells according to claim 10 , wherein the live virus liquid composition is administered prior to, simultaneously with or following the administration of a checkpoint inhibitor.

12 . The method according to claim 10 , wherein said live virus liquid composition comprises:

a herpes simplex-1 virus;

partially hydrolyzed gelatin at a concentration of 0.5% (w/v);

sorbitol at a concentration of 2% (w/v);

myo-inositol at a concentration of 4% (w/v);

sodium chloride at a concentration of 50 mM to 250 mM; and

sodium phosphate at a concentration of 80 mM to 120 mM,

wherein the composition is at pH 7-8.

13 . The method according to claim 12 , wherein said live virus liquid composition is at pH 7.4.

14 . The method according to claim 12 , wherein said herpes simplex-1 virus is talimogene laherparepvec.

15 . The method according to claim 13 , wherein said herpes simplex-1 virus is talimogene laherparepvec.

16 . A live virus liquid composition comprising: a herpes simplex-1 virus;

partially hydrolyzed gelatin at a concentration of 0.5% (w/v);

sorbitol at a concentration of 2% (w/v);

myo-inositol at a concentration of 4% (w/v);

sodium chloride at a concentration of 145 mM;

and sodium phosphate at a concentration of 80 mM to 120 mM,

wherein the composition is at pH 7.4.

17 . The live virus liquid composition according to claim 16 , wherein the herpes simplex-1 virus is talimogene laherparepvec.

18 . The method according to claim 10 or 12 , wherein the tumor cells are selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, medulloblastoma, melanoma cells, pancreatic cancer cells, prostate carcinoma cells, breast cancer cells, lung cancer cells, colon cancer cells, hepatoma cells, mesothelioma, bladder cancer cells, and epidermoid carcinoma cells.

19 . The method according to claim 18 , wherein the tumor cells are melanoma cells.

20 . The live virus liquid composition according to claim 17 , wherein the composition comprises sodium phosphate at a concentration of 102 mM.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2020
From: LITOWSKI, JENNIFER R.; SISKA, CHRISTINE CLAUDIA; KERWIN, BRUCE ARTHUR
To: AMGEN INC.
Reel/Frame 054153/0983 →
Continuity (3)
Continuation 15532988 · Dec 15, 2015
Provisional Application 62093663 · Dec 18, 2014
Related Publication 20210052680A1 · Feb 25, 2021
References Cited (113)
US 4337242A · Markus et al. · 1982 [cited by applicant]
US 4985244A · Makino · 1991 [cited by examiner]
US 5024836A · McAleer et al. · 1991 [cited by applicant]
US 5811097A · Allison et al. · 1998 [cited by applicant]
US 5824318A · Mohr · 1998 [cited by applicant]
US 5855887A · Allison et al. · 1999 [cited by applicant]
US 6051227A · Allison · 2000 [cited by applicant]
US 6207157B1 · Gu · 2001 [cited by applicant]
US 6682736B1 · Hanson · 2004 [cited by applicant]
US 6764675B1 · Whitley · 2004 [cited by applicant]
US 6770274B1 · Martuza · 2004 [cited by applicant]
US 6984720B1 · Korman · 2006 [cited by applicant]
US 7063835B2 · Coffin · 2006 [cited by applicant]
US 7168757B2 · Futatsuhashi · 2007 [cited by applicant]
US 7223593B2 · Coffin · 2007 [cited by applicant]
US 7488802B2 · Collins · 2009 [cited by applicant]
US 7605238B2 · Korman · 2009 [cited by applicant]
US 7744899B2 · Whitley · 2010 [cited by applicant]
US 7749745B2 · Johnson · 2010 [cited by applicant]
US 7943743B2 · Korman · 2011 [cited by applicant]
US 8008449B2 · Korman · 2011 [cited by applicant]
US 8084039B2 · Stinchcomb · 2011 [cited by examiner]
US 8217149B2 · Irving · 2012 [cited by applicant]
US 8273568B2 · Martuza · 2012 [cited by applicant]
US 8420071B2 · Whitley · 2013 [cited by applicant]
US 8470577B2 · Johnson · 2013 [cited by applicant]
US 10034938B2 · Vanderwalde · 2018 [cited by examiner]
US 20050164910A1 · Sakai et al. · 2005 [cited by applicant]
US 20060141483A1 · Calton · 2006 [cited by applicant]
US 20080248551A1 · Stinchcomb et al. · 2008 [cited by applicant]
US 20110243988A1 · Ohtake · 2011 [cited by examiner]
US 20130202639A1 · Kousoulas · 2013 [cited by examiner]
US 20150150964A1 · Anderson · 2015 [cited by examiner]
CN 101926990A · 2010 [cited by applicant]
JP S577423A · 1982 [cited by applicant]
JP 2643982B2 · 1997 [cited by applicant]
WO 199600007A1 · 1996 [cited by applicant]
WO 199639841A1 · 1996 [cited by applicant]
WO 199907394A1 · 1999 [cited by applicant]
WO 1999012568 · 1999 [cited by applicant]
WO 1999055348 · 1999 [cited by applicant]
WO WO9962500A1 · 1999 [cited by examiner]
WO 2000054795A1 · 2000 [cited by applicant]
WO 2003042402A2 · 2003 [cited by applicant]
WO 2003082200A2 · 2003 [cited by applicant]
WO 20054795A2 · 2005 [cited by applicant]
WO 2006002394A2 · 2006 [cited by applicant]
WO 2007132480 · 2007 [cited by applicant]
WO 2008156712A1 · 2008 [cited by applicant]
WO 2009014774A1 · 2009 [cited by applicant]
WO 2010036959A2 · 2010 [cited by applicant]
WO 2010089411A2 · 2010 [cited by applicant]
WO 2011032108 · 2011 [cited by applicant]
WO 2011066342A2 · 2011 [cited by applicant]
WO 2011082400A2 · 2011 [cited by applicant]
WO 2011119925A2 · 2011 [cited by applicant]
WO 2011159877A2 · 2011 [cited by applicant]
WO 2011161699A2 · 2011 [cited by applicant]
WO 2013006795A2 · 2013 [cited by applicant]
WO 2013106398A1 · 2013 [cited by applicant]
WO 2013177172A2 · 2013 [cited by applicant]
WO WO2014036412A2 · 2014 [cited by examiner]
WO 2016100364A1 · 2016 [cited by applicant]
WO 2017118864A1 · 2017 [cited by applicant]
WO 2017118865A1 · 2017 [cited by applicant]
WO 2017118866A1 · 2017 [cited by applicant]
WO 2017118867A1 · 2017 [cited by applicant]
WO 2017181420A1 · 2017 [cited by applicant]
WO 2018006005A1 · 2018 [cited by applicant]
WO 2018026872A1 · 2018 [cited by applicant]
WO 2018127713A1 · 2018 [cited by applicant]
WO 2020140012A1 · 2020 [cited by applicant]
Medicago (http://www.medicago.se/sites/default/files/pdf/ (See IDS Jan. 12, 2022; D2) productsheets/PBS_Buffer_v._01.pdf. (2010)) (Year: 2010). [cited by examiner]
Burger et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery vol. 21, No. 1, 2008, pp. 25-34. (Year: 2008). [cited by examiner]
Ambion 10X PBS pH 7.4, 2008. [cited by applicant]
Medicago, http://www.medicago.se/sites/default/files/pdf/productsheets/PBS_Buffer_v._01.pdf, (2010). [cited by applicant]
Russell et al., “Oncolytic virotherapy,” [cited by applicant]
Wang et al., “Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma,” [cited by applicant]
Berard A, Coombs KM (2009) Mammalian reoviruses: propagation, quantification, and storage. Current protocols in microbiology: 15C-1. [cited by applicant]
Cassady and Ness Parker, (2010) The Open virology Journal 4: 103-108. [cited by applicant]
CDC Media Statement on Newly Discovered Smallpox Specimens (n.d.). Available: http://www.cdc.gov/media/releases/2014/s0708-NIH.html. [cited by applicant]
Complete List of Vaccines Licensed for Immunization and Distribution in the US (n.d.). Available: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm. Date accessed Oct. 2, 2017. [cited by applicant]
Condit RC, Moussatche N, Traktman P (2006) In a nutshell: structure and assembly of the vaccinia virion. Advances in virus research 66: 31-124. [cited by applicant]
Essbauer S, Meyer H, Porsch-Özcürümez M, Pfeffer M (2007) Long-Lasting Stability of Vaccinia Virus (Orthopoxvirus) in Food and Environmental Samples. Zoonoses and public health 54: 118-124. [cited by applicant]
Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, et al. (2004) Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci 93: 2458-2475. [cited by applicant]
FDA found more than smallpox vials in storage room (n.d.). Available: https://www.washingtonpost.com/national/health-science/fda-found-more-than-smallpoxvials-in-storage-room/2014/07/16/850d4b12-0d22-11e4-8341-b8072ble7… [cited by applicant]
Kueltzo LA, Wang W, Randolph TW, Carpenter JF (2008) Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci 97: 1801-181… [cited by applicant]
Liu et al., (2013) World Journal of Gastroenterology 19(31): 5138-5143. [cited by applicant]
Liu et al., Gene Ther 10: 292-303, 2003. [cited by applicant]
Maclean et al., (1991) Journal of General Virology 79: 631-639. [cited by applicant]
McCollum AM, Li Y, Wilkins K, Karem KL, Davidson WB, et al. (2014) Poxvirus 25 viability and signatures in historical relics. Emerging infectious diseases 20: 177. [cited by applicant]
Meignier et al.,(1998) J. Infect. Dis. 159; 602-614. [cited by applicant]
Mettenleiter TC (2002) Herpesvirus assembly and egress. Journal of virology 76: 1537-1547. [cited by applicant]
Mineta et al. (1995) Nat Med. 1:938-943. [cited by applicant]
Mohr & Gluzman (1996) EMBO 15:4759-4766. [cited by applicant]
Mulvey et al. (1999) J Virology, 73:4, 3375-3385. [cited by applicant]
Roizman B (1982) The Family Herpesviridae: General Description, taxonomy and classification. The Viruses, vol. A, Herpesviruses. New York: Plenum Press. [cited by applicant]
Shahrokh M. Ghobadloo et al: “Carbohydrate-Based Ice Recrystallization Inhibitors Increase Infectivity and Thermostability of Viral Vectors”, Scientific Reports, vol. 4, Jan. 1, 2014 (Jan. 1, 2014), pp. 5903-5903, XP055… [cited by applicant]
Shen and Nemunaitis, “Herpes simplex virus 1 (HSV-1) for cancer treatment,” [cited by applicant]
Shire SJ (2009) Formulation and manufacturability of biologics. Current opinion in biotechnology 20: 708-714. [cited by applicant]
Sokhey J, Gupta CK, Sharma B, Singh H (1988) Stability of oral polio vaccine at different temperatures. Vaccine 6: 12-13. [cited by applicant]
Todo et al., (2001) Proc Natl Acad Sci USA, 98:6396-6401. [cited by applicant]
Varghese and Rabkin, (2002) Cancer Gene Therapy 9:967-97. [cited by applicant]
Vaccine Ingredients and Manufacturer Information, https://web.archive.org/web/20141112183109/https://vaccines.procon.org/view.resource.php?resourceID=005206, Nov. 12, 2014. [cited by applicant]
Varshney and Singh, Editors, “Lyophilized Biologics and Vaccines,” © Springer Science+Business Media, New York 2015. [cited by applicant]
Hansen et al., “Freeze-drying of live virus vaccines: A review,” [cited by applicant]
International Search Report in PCT Application No. PCT/US2019/068700 dated Apr. 6, 2020, 3 pages. [cited by applicant]
Office Action in Japanese Patent Application No. 2021-537096 dated Nov. 10, 2023 with English translation. [cited by applicant]
Rheinbaben et al., “Environmental resistance, disinfection, and sterilization of poxviruses,” in: Mercer, Schmidt, Weber, editors, 2007, pp. 397-405, Poxviruses (2007). [cited by applicant]
Roy et al., “Troubleshooting During the Manufacture of Lyophilized Drug Product-Being Prepared for the Unexpected,” [cited by applicant]
Thompson et al., “DNA Sequence and RNA Transcription through a Site of Recombination in a Non-neurovirulent Herpes Simplex Virus Intertypic Recombinant,” [cited by applicant]
White et al., “Development of a stable liquid formulation of live attenuated influenza vaccine,” [cited by applicant]
Yannarell et al., “Stabilizing cold-adapted influenza virus vaccine under various storage conditions,” [cited by applicant]